BCAB
What one share of Bioatla holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics (“CAB” or “CABs”) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target.
Bioatla’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$22.73 |
|---|---|
| Cash and investments | $0.93 |
| Book value | −$21.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.43 | −$138.02 | — | −$90.01 | — | $294.45 |
| 2022 | — | −$136.77 | — | −$116.14 | — | $194.60 |
| 2023 | — | −$129.21 | — | −$108.85 | — | $73.50 |
| 2024 | — | −$71.83 | — | −$74.05 | — | $12.28 |
| 2025 | — | −$50.66 | — | −$40.97 | — | −$28.51 |